Pulmatrix (NASDAQ:PULM) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Pulmatrix (NASDAQ:PULM) in a report published on Monday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Pulmatrix Price Performance

Shares of NASDAQ:PULM opened at $6.26 on Monday. The firm has a fifty day moving average price of $6.54 and a two-hundred day moving average price of $6.29. Pulmatrix has a one year low of $1.72 and a one year high of $10.40. The company has a market cap of $22.85 million, a price-to-earnings ratio of -2.37 and a beta of 1.38.

Pulmatrix (NASDAQ:PULM) last posted its quarterly earnings results on Friday, March 21st. The biotechnology company reported ($0.54) earnings per share for the quarter. Pulmatrix had a negative return on equity of 45.97% and a negative net margin of 96.51%.

Institutional Investors Weigh In On Pulmatrix

An institutional investor recently raised its position in Pulmatrix stock. Geode Capital Management LLC increased its holdings in shares of Pulmatrix, Inc. (NASDAQ:PULM) by 24.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 36,871 shares of the biotechnology company’s stock after acquiring an additional 7,290 shares during the period. Geode Capital Management LLC owned approximately 1.01% of Pulmatrix worth $257,000 at the end of the most recent reporting period. 11.84% of the stock is currently owned by institutional investors.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.